Lunaphore Technologies, a Switzerland-based medtech firm is developing innovative next-generation devices for cancer tissue diagnostics; they recently closed a CHF 5.3M Series B funding in August 2018, which will enable the CE marking of their products, and support Lunaphore’s product launch in the future.
According to Start-up Ticker, Lunaphore’s CEO, Ata Tuna Ciftlik, said: “Following the announcement of partnerships in the last months, Lunaphore’s standing as a key and enabling technology in the tissue diagnostic market has been validated one more time with this oversubscribed financing round. Our management team is thrilled by the investors’ confidence and interest”.
Backers included Occident Group, Zürcher Kantonalbank, as well as investment funds from Asia, Switzerland and United Kingdom.
Lunaphore’s medical solution is still in development at this time and is not on sale, but it aims to produce rapid immunostainings; it has already demonstrated good results during tests conducted with cancer patient samples.
